Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 11/20 | 0.60 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.60 |
| ▸ | CNR1 | P21554 | 5/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311941 | 0.90 | FYN (0.52) | XDHSLC22A12FYN | |
| SCHEMBL4194358 | 0.87 | XDH (0.60) | XDHSLC22A12FYN | |
| SCHEMBL4194098 | 0.85 | XDH (0.64) | XDHSLC22A12CNR1FYNTDP2 | |
| SCHEMBL21311940 | 0.85 | FYN (0.53) | XDHSLC22A12FYN | |
| SCHEMBL4189068 | 0.85 | FYN (0.46) | XDHSLC22A12FYN | |
| SCHEMBL4143146 | 0.82 | XDH (0.62) | XDHSLC22A12FYN | |
| SCHEMBL4183096 | 0.82 | ABCG2 (0.52) | XDHSLC22A12FYN | |
| SCHEMBL4191653 | 0.82 | XDH (0.53) | XDHSLC22A12CNR1CNR2KCNH2 | |
| SCHEMBL4194129 | 0.81 | FYN (0.67) | XDHSLC22A12CNR1FYNCNR2 | |
| SCHEMBL4164292 | 0.81 | HSD17B1 (0.54) | XDHSLC22A12FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | XDH 750/4885SLC22A12 4511/4885CNR1 3831/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885CNR1 3922/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885CNR1 3922/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885CNR1 3922/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | XDH 527/4885SLC22A12 2928/4885CNR1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.